Estrella Immunopharma, Inc. (ESLA): Nasdaq/NYSE listing notice — Estrella Immunopharma receives Nasdaq deficiency notice for failure to hold annual meeting

Estrella Immunopharma, Inc.

Received Nasdaq letter on Jan 7, 2026, citing non-compliance with Listing Rule 5620(a) for not holding annual meeting.
Company has 45 calendar days to submit a plan to regain compliance.
Expects to convene annual meeting in April 2026 and will consult with Nasdaq on compliance.
No immediate impact on listing or trading of ESLA common stock or ESLAW warrants.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Estrella Immunopharma, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

January 7, 2026, Estrella Immunopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. The Letter also referenced the compliance plan procedures under Nasdaq Listing Rule 5810(c)(2)(G). The Letter states that the Company has 45 calendar days to submit a plan to regain compliance. The Company intends to submit its compliance

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-003998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.